🔎 Trials Near Me

Nyumbani › Sarcoma ya Tishu Laini › Texas › Houston

Majaribio ya kliniki ya Sarcoma ya Tishu Laini katika Houston, TX

Masomo 32 ya Sarcoma ya Tishu Laini yanatafuta washiriki katika vituo vya Houston na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.

Maandishi rasmi ya utafiti (Kiingereza)

Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

InaajiriUtafiti wa uchunguziWajitolea wenye afya wanakaribishwa
  • UT MD Anderson Cancer Center, Houston
Umri 40 hadi 75 · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT05334069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

InaajiriHatua 2
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT06760819

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

InaajiriHatua 1/2
  • MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 1 Okt 2026 · NCT07189871

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

InaajiriHatua 1/2
  • UT MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 29 Sep 2026 · NCT06498648

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

InaajiriHatua 1/2
  • Baylor College of Medicine, Houston
Hadi umri 25 · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT04094610

Anti-GD2 ADC M3554 in Advanced Solid Tumors

InaajiriHatua 1
  • The University of Texas MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 22 Sep 2026 · NCT06641908

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

InaajiriHatua 1
  • The University of Texas MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 18 Sep 2026 · NCT07705334

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

InaajiriHatua 1/2
  • University Of Texas MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 11 Sep 2026 · NCT06797999

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

InaajiriHatua 1
  • UT MD Anderson Cancer Center, Houston
Umri 12 hadi 85 · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT03715933

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

InaajiriHatua 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT05732831

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

InaajiriHatua 1
  • UT MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 4 Sep 2026 · NCT05711615

Actinium Therapy for Late-stage Aggressive Sarcomas

InaajiriHatua 1
  • MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 28 Ago 2026 · NCT07156565

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

InaajiriHatua 1/2
  • MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 25 Ago 2026 · NCT06975293

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

InaajiriUtafiti wa uchunguzi
  • M D Anderson Cancer Center, Houston
Umri wote · Jinsia zote · Imesasishwa 21 Ago 2026 · NCT01772771

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

InaajiriHatua 2
  • MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 20 Ago 2026 · NCT07283731

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

InaajiriHatua 1
  • MD Anderson Cancer Center, Houston
Umri 12 na zaidi · Jinsia zote · Imesasishwa 18 Ago 2026 · NCT06474676

A Study of MGC026 in Participants With Advanced Solid Tumors

InaajiriHatua 1
  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 11 Ago 2026 · NCT06242470

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Inaajiri
  • M D Anderson Cancer Center, Houston
Umri 10 na zaidi · Jinsia zote · Imesasishwa 11 Ago 2026 · NCT04199026

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

InaajiriHatua 1
  • The University of Texas M. D. Anderson Cancer Center, Houston
Umri 1 hadi 30 · Jinsia zote · Imesasishwa 6 Ago 2026 · NCT07444619

IDOV-Immune for Advanced Solid Tumors

InaajiriHatua 1
  • MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 5 Ago 2026 · NCT06910657

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

InaajiriUtafiti wa uchunguzi
  • MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 15 Jul 2026 · NCT07377747

Lead-212 PSV359 Therapy for Patients With Solid Tumors

InaajiriHatua 1/2
  • MD Anderson Cancer Center, Houston
Umri 18 hadi 90 · Jinsia zote · Imesasishwa 6 Jul 2026 · NCT06710756

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

InaajiriHatua 2
  • M D Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 11 Jun 2026 · NCT04771520

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

InaajiriHatua 1
  • MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 11 Jun 2026 · NCT06789172

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

InaajiriHatua 1/2
  • MD Anderson Cancer Center, Houston
Umri 12 na zaidi · Jinsia zote · Imesasishwa 27 Mei 2026 · NCT03093116

Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

InaajiriHatua 2
  • M.D. Anderson Children's Cancer Hospital, Houston
Umri 8 hadi 30 · Jinsia zote · Imesasishwa 22 Mei 2026 · NCT05726383

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Inaajiri
  • M D Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 15 Apr 2026 · NCT04693377

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

InaajiriHatua 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Umri 2 hadi 30 · Jinsia zote · Imesasishwa 3 Feb 2026 · NCT05734066

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

InaajiriHatua 1
  • Texas Children's Hospital, Houston
Umri 1 hadi 25 · Jinsia zote · Imesasishwa 22 Jan 2026 · NCT04995003

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

InaajiriHatua 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 11 Des 2025 · NCT06943521

BostonGene and Exigent Genomic INsight Study

InaajiriUtafiti wa uchunguzi
  • Oncology Consultants, Houston
Umri 18 na zaidi · Jinsia zote · Imesasishwa 17 Feb 2025 · NCT06272864

Majaribio ya Sarcoma ya Tishu Laini katika miji mingine

Masomo mengine katika Houston

Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.